Keap1 deletion accelerates mutant K-ras/p53-driven cholangiocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The Kelch-like ECH-associated protein 1 (Keap1)-NF-E2-related factor 2 (Nrf2) pathway is implicated in cancer progression and oxidative stress responses.
• Loss-of-function Keap1 mutations activate Nrf2, contributing to cancer development.

Purpose of the Study:

• To investigate the role of Keap1 deletion in cholangiocarcinoma development using a K-ras/p53 mutant mouse model.
• To identify molecular mechanisms linking Keap1 loss to cholangiocarcinoma progression.

Main Methods:

• Utilized a liver-specific Keap1 deletion in a K-ras/p53 mutant mouse model.
• Conducted comprehensive gene expression profiling to analyze molecular changes.
• Examined the expression of Nrf2-target genes and cholangiocyte-related genes, including Sox9.

Main Results:

• Liver-specific Keap1 deletion in K-ras/p53 mutant mice accelerated invasive cholangiocarcinoma formation.
• Observed broad upregulation of Nrf2-target genes (e.g., Nqo1, Gstm1) and cholangiocyte-related genes.
• Found high expression of the transcriptional factor Sox9 in dysplastic bile ducts, correlating with Nrf2 activation.

Conclusions:

• The Keap1-Nrf2 pathway activation, coupled with Sox9 upregulation, drives cholangiocarcinoma progression.
• The Keap1-Nrf2-Sox9 axis represents a potential novel therapeutic target for cholangiocarcinoma.
• Keap1 deletion accelerates cholangiocarcinoma formation and promotes cholangiocyte differentiation via Nrf2 activation.